Inovio

529 articles about Inovio

• INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19

  6/30/2020

  Inovio (NASDAQ:INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to protect and treat people from infectious diseases and cancer, today announced positive interim clinical data of INO-4800, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the first two Phase 1 clinical trial cohorts.

• 

  Inovio’s COVID-19 Vaccine Suggests Overall Immune Responses in Phase I Trial

  6/30/2020

  INO-4800 is one of the experimental vaccines included in the U.S. government’s Operation Warp Speed that has a goal of having a vaccine available by January 2021.
• 

  BioSpace Movers & Shakers, June 26

  6/26/2020

  Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.

• INOVIO Expands Senior Management Team

  6/25/2020

  Company Appoints President for INOVIO Asia; Adds Senior Vice President of COVID-19 Vaccine Clinical Development

• INOVIO Receives $71 Million Contract From U.S. Department of Defense To Scale Up Manufacture of CELLECTRA® 3PSP Smart Device and Procurement of CELLECTRA® 2000 for COVID-19 DNA Vaccine

  6/23/2020

  - U.S. Government will support the scale-up of INOVIO's proprietary intradermal DNA delivery device CELLECTRA® 3PSP to deliver INOVIO's COVID-19 vaccine - INOVIO to report on interim U.S. Phase 1 clinical trial results in late June - INOVIO preparing for U.S. Phase 2/3 efficacy study to begin this summer   [23-June-2020]   PLYMOUTH MEETING, Pa. , June 2

• INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine (INO-4800) in South Korea

  6/4/2020

  First COVID-19 vaccine clinical study approved in South Korea funded by CEPI through INOVIO, and supported by KCDC/KNIH

• INOVIO to Host Webinar "DNA Medicines: From COVID-19 to Cancer"

  5/26/2020

  Leading Researchers and Scientists Detail INOVIO's Proprietary DNA Medicines Technology; Provide Updates on INO-4800 COVID-19 DNA Vaccine and INO-5401 GBM DNA Immunotherapy

• INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models

  5/20/2020

  Publication in Nature Communications demonstrates generation of robust neutralizing antibodies and T cell responses against SARS-CoV-2

• INOVIO to Present at RBC Capital Markets Virtual Global Healthcare Conference

  5/12/2020

  INOVIO (NASDAQ:INO) today announced that Dr. J. Joseph Kim , President and CEO, along with other members of management will present in a fireside discussion at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020 at 2:30 p.m. Eastern Time . This fireside discussion will be held virtually and a live w

• INOVIO Reports First Quarter 2020 Financial Results; Provides Business Update

  5/11/2020

  U.S. Phase 1 clinical trial for COVID-19 vaccine candidate INO-4800 completed enrollment with 40 healthy volunteers; preliminary results expected in late June

• INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI

  4/30/2020

  INOVIO and Richter-Helm BioLogics will expand existing DNA manufacturing agreement to support large-scale manufacturing of INO-4800

• INOVIO Completes Enrollment in the Phase 1 U.S. Trial of INO-4800 for COVID-19 DNA Vaccine; Interim Results Expected in June

  4/28/2020

  INO-4800 Phase 2/3 U.S. clinical trial being prepared to start this summer Parallel preclinical challenge studies ongoing

• INOVIO to Report First Quarter 2020 Financial Results on May 11, 2020

  4/27/2020

   INOVIO (NASDAQ:INO) announced today that first quarter 2020 financial results will be released after the market close on May 11, 2020 . Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update, including the company's

• 

  Biopharma Industry News: Update on the Novel Coronavirus

  3/17/2020

  As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection ...

• Inovio Pharmaceuticals to Present at Upcoming Investor Conferences - Sept. 3, 2019

  9/3/2019

  Inovio Pharmaceuticals, Inc. announced that Joseph Kim, President and CEO, will present an Inovio overview and business update at two upcoming investor conferences

• 

  QIAGEN and Inovio Team Up to Create Companion Diagnostic for HPV Cervical Dysplasia

  5/17/2019

  The collaboration will focus on Inovio’s VGX-3100, which stimulates a specific immune response to HPV-16 and HPV-18, targeting the infection and causing destruction of precancerous cells.

• Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

  5/16/2019

  Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100

• Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR

  4/2/2019

  Data demonstrates tumor-clearing ability of Inovio's dBiTE technology in preclinical cancer model

• Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor

  4/1/2019

  Inovio Pharmaceuticals, Inc. announced that its Phase 1/2 immuno-oncology trial in patients with newly diagnosed glioblastoma has completed its enrollment three months ahead of schedule.

• Inovio Appoints Global Commercial Leader to its Board of Directors

  3/25/2019

  Inovio Pharmaceuticals, Inc. announced the appointment of Dr. Ann C. Miller to its Board of Directors.